CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP)
Health Care · Clinical-stage biopharmaceutical development · NASDAQ
Clinical-stage biopharmaceutical company developing next-generation antibody drug conjugates for oncology and a CB1 receptor inverse agonist for obesity.
What CORBUS PHARMACEUTICALS HOLDINGS IN does
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and obesity. The company's lead program, CRB-701, is a next-generation antibody drug conjugate targeting Nectin-4 expression on cancer cells designed to improve upon approved therapies like PADCEV® with better tolerability and efficacy. The company is also developing CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity treatment. Corbus operates clinical trials in the US, Europe, and China, with CRB-701 having received fast track FDA designation for cervical cancer and head and neck squamous cell carcinoma.
Themes: ["Oncology / cancer therapeutics","Antibody drug conjugates (ADCs)","Head and neck cancer","Cervical cancer","Urothelial cancer","Obesity / weight management","CB1 receptor antagonism"]
Fundamentals
- Price$9.66 as of 2026-07-09 close
- Market cap$177M as of 2026-07-10
- 1-year return+15.4% as of 2026-07-09 close
- Net margin-2838.7% as of 2026-07-10
- ROE-70.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.62 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Seagen (SGEN) – ADC developer and acquired by Pfizer
- Astellas Pharma – Co-developer of PADCEV®
- Eli Lilly (LLY) – GLP-1 and obesity therapeutics
- Novo Nordisk (NVO) – GLP-1 and obesity therapeutics
- Ayala Pharmaceuticals
- Sutro Biopharma – ADC platform developer
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.